Where Did the Authors Work When They Conducted Their Clin... | NCT07115680

Studies
Where Did the Authors Work When They Conducted Their Clinical Pharmacology Studies?

NCT07115680

Sponsor

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Status

Completed

Last Update Posted

Dec 19, 2025Actual

Enrollment

503Actual

Phase

Not provided

Conditions

Scientific Collaboration in Clinical Pharmacology

Interventions

human participants, data or material

Countries

Spain

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Dec 2025

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Sep 15, 2025Actual

Primary Completion Date

Nov 4, 2025Actual

Completion Date

Nov 30, 2025Actual

First Submitted Date

Aug 4, 2025

First Submission Date that Met QC Criteria

Aug 8, 2025

First Posted Date

Aug 11, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Dec 12, 2025

Last Update Posted Date

Dec 19, 2025Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

It is unknown in which countries the clinical pharmacology studies published in leading specialized journals were conducted. The hypothesis is that studies in this specialty tend to be conducted and published by authors from a single country. This analysis aims to describe the number of collaborators and the countries in which they worked, using the Nature Index concept of "share."

Detailed Description

Original articles (full reports, short communications, research letters) on human participants, data, or material published in the seven top (as per Journal Citations Report 2024 Impact Factor) clinical pharmacology hybrid journals linked to clinical pharmacology professional societies will be included. Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first. The country of the main authors (first author/last author) and the countries where all the contributors listed in the article's byline worked will be recorded. Collaboration index and degree of collaboration will be calculated. The contribution of all countries will be calculated using the Nature index's "share" concept.Depending on whether a high percentage of articles are written by authors from the same country as a given journal (and scientific society), the need to adjust the results to reflect a situation closer to reality in terms of the importance of different countries in the publication of the articles evaluated will be assessed. As a proxy, the relevance of each country in contributing to clinical pharmacology research will be calculated by multiplying the "share" score by the JCR impact factor of each journal and adding the scores obtained from the seven journals. In addition, In addition, following slightly modified terminology used by ClinicalTrials.gov, the type of sector (industry, government institutions, and 'Others') will also be recorded to help characterize the studies evaluated. However, the 'Others' category will be classified into hospitals, universities, and research centers. Funding will be recorded as public, private, and public-private.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

503Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Single-country studies		Multinational studies	Other: human participants, data or material

Interventions

Name	Type	Description	Arm Group Labels	Other Names
human participants, data or material	Other	Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
countries where authors conducted their study	The country of the principal authors and of all collaborators will be registered following Nature Index 'share' concept	Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Articles on human participants, data or material. Original articles, short reports, research letters.

Exclusion Criteria:

In vitro studies, animal studies. Editorials, letters, commentaries, perspectives.

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

All original research articles published in the six top clinical pharmacology hybrid journals

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Rafael Dal-Re, MD, PhD, MPH	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Health Research Institute Fundación Jiménez Díaz		Madrid		28036	Spain

IPD Sharing Statement Module

Plan to Share IPD

Description

All data to be used in this study are in the public domain.

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided